Enzo Biochem, Inc.
ENZB · OTC
7/31/2024 | 7/31/2023 | 7/31/2022 | 7/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 2.7% | -71% | -9.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 45.9% | 37.2% | 39.2% | 45.5% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | $0 |
| % Margin | -30.8% | -79.6% | -14.5% | 8.4% |
| Other Income/Exp. Net | $0 | -$0 | -$0 | $0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | $0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | $0 | -$0 | $0 |
| % Margin | -81.7% | 65.3% | -21.1% | 2.9% |
| EPS | -0.51 | -1.27 | -0.46 | 0.071 |
| % Growth | 59.8% | -176.1% | -747% | – |
| EPS Diluted | -0.51 | -1.27 | -0.46 | 0.071 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | $0 |
| % Margin | -26.2% | -71.9% | -14% | 2.8% |